← All stocks

Rapport Therapeutics, Inc.

RAPP Mostly scheduled

CIK 0002012593 #1932 in the set updated 17 Sep 2026

Bought (12 mo)

$0.00

out of their own pocket, the only kind of buying there is

Sold (12 mo)

$49.11M

$48.62M on a plan · $150.49K straight out of an exercise

Sold at will

$340.94K

3 of 74 sales

Net

−$49.11M

−$340.94K against sales at will

By person

9 insiders · 75 transactions

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Third Rock Ventures V, L.P. entity

10% owner

—

$34.39M (5) scheduled

−$34.39M

6,280,525

13.09%

$289.00M

−12.0%

Ceesay Abraham

Chief Executive Officer

—

$7.99M (38) scheduled

−$7.99M

582,164

1.21%

$26.79M

−28.2%

Yeleswaram Krishnaswamy

Chief Development Officer

—

$4.46M (11) scheduled

−$4.46M

195,862

0.4082%

$9.01M

−32.7%

Bredt David

Chief Scientific Officer

—

$1.36M (12) scheduled

−$1.36M

393,075

0.8193%

$18.09M

−23.5%

Gault Cheryl

Chief Operating Officer

—

$906.41K (8) scheduled

−$906.41K

149,914

0.3125%

$6.90M

−5.1%

PAUL STEVEN M

Director

—

41,666

0.0868%

$1.92M

—

Huber Reid M

Director

—

20,400

0.0425%

$938.70K

—

Ignelzi Troy A.

Chief Financial Officer

—

10,000

0.0208%

$460.15K

—

Young Wendy B.

Director

—

9,500

0.0198%

$437.14K

—

Individual transactions

Nothing of that kind in this period.

What was left out

Form 4 filings counted 48

Amendments (4/A) skipped 0

Filings about a different issuer 0

Unreadable filings 0

Joint filings 4

Sales on a Rule 10b5-1 plan 70

Sales straight out of an exercise 1

Sales at will 3

Transactions with no price 0

Shares from compensation/vesting 38,000

History held since 10 Jun 2024